Diana Garcia-Drago

Rehovot, M 76100, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

Journal: EMBO molecular medicine
Published: June 07, 2025

Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse.

Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse.

Journal: Science signaling
Published: April 22, 2025

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.

Journal: Cancer discovery
Published: January 28, 2022

TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.

TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.

Journal: Science signaling
Published: June 23, 2021

Reduced Lamin A/C Does Not Facilitate Cancer Cell Transendothelial Migration but Compromises Lung Metastasis.

Reduced Lamin A/C Does Not Facilitate Cancer Cell Transendothelial Migration but Compromises Lung Metastasis.

Journal: Cancers
Published: May 05, 2021

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

Journal: Cell reports
Published: March 11, 2021

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.

Journal: Cancer research
Published: October 22, 2020

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.

Journal: Cancers
Published: July 23, 2020

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.

Journal: EMBO molecular medicine
Published: July 20, 2020

ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma.

ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma.

Journal: Cell reports
Published: November 18, 2018

Nonredundant, Highly Connected MicroRNAs Control Functionality in Breast Cancer Networks.

Nonredundant, Highly Connected MicroRNAs Control Functionality in Breast Cancer Networks.

Journal: International journal of genomics
Published: March 02, 2018
Showing 1-11 of 11

Last Updated: 09/26/2026